Allogene Therapeutics Inc
ALLO
$3.51
Closing
▲0.29%
1D
▲9.35%
YTD
Market cap
$593.51M
52 week high
$6.89
52 week low
$2.23
Volume
882,735
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$593.51M
Analysts' Rating
BUY
Price Target (Mean)
13.92308
Total Analysts
17
P/E
Operating Margin
-146453.49%
Beta
0.85
Revenue Growth (Annual)
-99.37%
52 week high
$6.89
52 week low
$2.23
Div. Yield
%
EPS Annual Growth
-30.19
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell-driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.
